Medicinal Cannabis Matters: Friday Roundup - 16 October 2026

What Does the Evidence Tell Us About Medicinal Cannabis and Menopause

Menopause can bring a range of physical and emotional changes, including disrupted sleep, anxiety, joint pain and hot flushes. While established treatments are available, some women continue to experience symptoms that affect their daily lives, prompting questions about whether medicinal cannabis could offer another option.

A new article from Cannabis Health explores the growing interest in medicinal cannabis for menopause and what the current evidence tells us.

Some women report using cannabis to manage symptoms such as sleep difficulties, anxiety and chronic pain. A Canadian survey involving 1,485 respondents found that cannabis use was relatively common among participants, with sleep difficulties, anxiety and muscle or joint aches among the reasons reported for use.

Any decision to consider treatment should take account of a patient's medical history, symptoms, previous treatments and existing medication. The growing interest in medicinal cannabis and menopause highlights the need for research that reflects women's experiences and investigates which treatments may help.

The Endocannabinoid System: Understanding the Science Behind Medicinal Cannabis

The endocannabinoid system (ECS) is a signalling network found throughout the human body. It helps regulate a range of physiological processes, including pain perception, appetite, sleep, mood and immune activity. Despite its relevance to cannabinoid medicine, many people remain unfamiliar with how the system works. A new article from Cannabis Health examines the science behind the ECS, why it matters to clinicians and what researchers are still trying to understand.

THC and CBD, two well-known compounds found in cannabis, interact with this system in different ways. THC can activate cannabinoid receptors, helping to explain some of its effects. CBD has a more complex mechanism and acts on multiple molecular targets rather than simply activating the same receptors in the same way.

The article also discusses the hypothesis of clinical endocannabinoid deficiency, which proposes that changes in endocannabinoid signalling could contribute to certain conditions, including migraine and fibromyalgia. This remains a research hypothesis rather than an established diagnosis, and there is currently no validated routine test that can diagnose an endocannabinoid deficiency in an individual patient.

Research into the ECS continues to develop, with scientists investigating how it interacts with other biological systems and whether particular pathways could provide useful targets for future treatments. Improving education about the ECS may also help healthcare professionals better understand cannabinoid medicines, their potential effects and their limitations.

Could Industrial Hemp Help the UK Reach its Environmental Targets?

Medicinal cannabis is often discussed in the context of healthcare, but the wider cannabis plant also has potential applications beyond medicine.

A new report highlighted by Business of Cannabis argues that industrial hemp could play a greater role in helping the UK meet its environmental targets, particularly through its potential uses in construction, agriculture and other industries.

The report, Opportunities from Industrial Hemp, was launched by the Cannabis Industry Council and calls for changes to the way industrial hemp is regulated in the UK. It argues that the current licensing framework creates barriers that could limit the development of the sector.

It is also important to recognise that hemp is not a single solution to the UK's environmental challenges. Its overall benefits depend on factors such as how it is grown, processed, transported and used, as well as how it compares with alternative materials.

Nevertheless, the report adds to the discussion about how industrial hemp could contribute to more sustainable materials and new economic opportunities. It also highlights how regulation can influence the development of industries connected to the wider cannabis plant.

At Medicann, we believe patients should have access to clear, evidence-led information and personalised clinical support throughout their treatment journey.

If you’re considering whether medicinal cannabis may be suitable for your condition, you can check your eligibility online in just two minutes.

Disclaimer: This blog post and the following featured articles are for information only and any articles on external platforms may be amended at any time. Articles that we refer to in our weekly roundup do not reflect the views of Medicann.